Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Zealand Pharma A/S
  6. Summary
    ZEAL   DK0060257814

ZEALAND PHARMA A/S

(ZEAL)
  Report
Delayed Nasdaq Copenhagen  -  10:59 2022-12-02 am EST
209.60 DKK   +3.25%
12:06pTransactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
GL
12:05pTransactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
AQ
12:01pZealand Pharma grants sign-on warrants and performance stock units under the employee warrant program and management long-term incentive program
GL
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Copenhagen
11/28/2022 11/29/2022 11/30/2022 12/01/2022 12/02/2022 Date
195.3(c) 197(c) 201.4(c) 203(c) 209.6(c) Last
160 314 137 044 291 480 223 779 196 486 Volume
+1.61% +0.87% +2.23% +0.79% +3.25% Change
More quotes
Estimated financial data (e)
Sales 2022 139 M 19,7 M 19,7 M
Net income 2022 -1 023 M -144 M -144 M
Net cash position 2022 934 M 132 M 132 M
P/E ratio 2022 -8,42x
Yield 2022 -
Sales 2023 896 M 126 M 126 M
Net income 2023 -174 M -24,6 M -24,6 M
Net cash position 2023 1 302 M 184 M 184 M
P/E ratio 2023 655x
Yield 2023 -
Capitalization 10 435 M 1 472 M 1 472 M
EV / Sales 2022 68,1x
EV / Sales 2023 10,2x
Nbr of Employees 203
Free-Float 99,4%
More Financials
Company
Zealand Pharma A/S is a Denmark-based biotechnology company. The Company is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The Company's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product... 
More about the company
Ratings of Zealand Pharma A/S
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about ZEALAND PHARMA A/S
12:06pTransactions in Zealand Pharma shares and/or related securities by persons discharging ..
GL
12:05pTransactions in Zealand Pharma shares and/or related securities by persons discharging ..
AQ
12:01pZealand Pharma grants sign-on warrants and performance stock units under the employee w..
GL
12:00pZealand Pharma grants sign-on warrants and performance stock units under the employee w..
AQ
11/17Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee War..
GL
11/17Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee War..
AQ
11/17Transactions in Zealand Pharma shares and/or related securities by persons discharging ..
GL
11/10Transcript : Zealand Pharma A/S, Q3 2022 Earnings Call, Nov 10, 2022
CI
11/10Zealand Pharma Announces Financial Results for the First Nine Months of 2022
GL
11/10Zealand Pharma A/S Reports Earnings Results for the Third Quarter and Nine Months Ended..
CI
11/10Zealand Pharma A/S Reports Earnings Results for the Third Quarter and Nine Months Ended..
CI
11/09Zealand Pharma to Participate in Upcoming November 2022 Investor Conferences
AQ
11/08Zealand Pharma to Participate in Upcoming Investor Conferences
GL
11/08Zealand Pharma to Participate in Upcoming Investor Conferences
AQ
11/03Zealand Pharma Hosts Conference Call on November 10 at 4pm CET (10am ET) to Present Thi..
GL
More news
News in other languages on ZEALAND PHARMA A/S
11/16Opiniones de los analistas del día: ArcelorMittal, Gi..
11/16Avis d'analystes du jour : ArcelorMittal, Crédit Agricole, Scor..
11/10Zealand Pharma A/S annonce ses résultats pour le troisième trimestre et les neuf mois t..
11/10Zealand Pharma A/S annonce ses résultats pour le troisième trimestre et les neuf mois t..
10/12Le poids des mots
More news
Analyst Recommendations on ZEALAND PHARMA A/S
More recommendations
ETFs positioned on ZEALAND PHARMA A/SETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
Fidelity Digital Health ACC - USD1.33%3.30%-NC
IShares MSCI Europe Small-Cap ETF - USD0.06%1.80%Europe
Vanguard FTSE All-World ex-US Small-Cap ETF - USD0.05%2.37%World
IShares MSCI EAFE Small-Cap ETF - USD0.03%1.75%EAFE
Vanguard MSCI International Small Companies...0.01%0.07%-World
More ETFs positioned on ZEALAND PHARMA A/S
Chart ZEALAND PHARMA A/S
Duration : Period :
Zealand Pharma A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ZEALAND PHARMA A/S
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 203,00 DKK
Average target price 235,83 DKK
Spread / Average Target 16,2%
EPS Revisions
Managers and Directors
Adam Sinding Steensberg President & Chief Executive Officer
Henriette Wennicke Chief Financial Officer
Alf Gunnar Martin Nicklasson Chairman
Ivan M. M°ller Executive VP-Technical Development & Operations
Danilo Verge Head-Global Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
ZEALAND PHARMA A/S39.90%1 436
VERTEX PHARMACEUTICALS46.07%81 217
REGENERON PHARMACEUTICALS, INC.19.03%80 283
BIONTECH SE-34.26%40 589
WUXI APPTEC CO., LTD.-32.53%32 137
GENMAB A/S25.29%29 594